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play response data. Analysis by question, category and demographic descriptor was 
performed. Results: 90% of learners were able to apply the content of the training 
within 4 weeks. Learners reported a notable increase in improving animal health 
and production as a result of the training. Most learners (> 90%) view the program 
as a worthwhile investment in their career. Significantly less managers feel the 
same way (< 45%). A ROI calculation result for total percent job improvement due to 
training is 1.7 times the top 25% benchmark. Surprisingly, those with greater than 
10 years tenure find the program to be just as worthwhile or more compared to the 
other tenure groups and the group with the largest number of employees also saw 
the greatest Job Impact from the training. ConClusions: The training provides 
much needed resources for the industry since most learners found it a worthwhile 
investment and the ROI calculation is high. This analysis allows for data driven 
decisions to be made for program adjustment and learner selection.
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objeCtives: In a previous study we found a steep increase in the use of the term 
“patient-centered” in the published literature from < 10 articles in the 1960s to > 3000 
in the 2010s. We also noted an increase in the proportion of articles in each decade 
reporting original research (17 vs 90%). The objective of this study was to further 
examine the subset of articles reporting original research. Methods: We searched 
EMBASE for articles written in English between 1950-2013 with ‘patient-centered’ in 
the title or abstract. We selected a random sample of 10 articles within each decade 
and captured data from the title and abstract on the focus of the article (healthcare, 
research, or teaching). We selected those focused on research and extracted additional 
data on the study design, data collection methods, number of cases, comparator 
group, and statistics used. We examined trends in these variables over time using 
tabular and graphical methods. Results: Our search identified 5051 publications, 
of which 2222 reported original research, from 1966-2013. Articles in earlier decades 
tended to report qualitative research (> 55%), whereas articles published since 2010 
used more sophisticated study designs (> 75%). The majority of studies in all decades 
employed descriptive statistics; however multivariate methods were used in 25% 
of studies in the 2010s. The use of a comparator group (16 vs 50%) and the average 
number of subjects (38 vs 687) also increased steadily over time. ConClusions: In 
addition to the increase in original research publications with “patient-centered” 
in the title or abstract over the last 50 years, we observed an increase in scientific 
and methodological rigor among these original research articles. These findings are 
consistent with the rise in personalized-medicine in the healthcare industry today, 
as well as the upsurge in the use of patient-reported outcome data that characterizes 
clinical research today.
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objeCtives: Patients with barriers such as normal anxiety around illness, low asser-
tiveness, or cognitive issues may have trouble communicating with their healthcare 
providers (HCP). HCPs are under increasing pressure to see more patients daily. Can 
a web-based training and worksheet help patients have improved outcomes, even in 
the face of these challenges? Methods: US and European patients were trained to 
produce an electronic, printable worksheet that contained the following: a detailed 
description of their primary complaint, including location, duration, and intensity 
according to Likert scale, correlation to activity, quality, and history. The worksheet 
also included a functional impact statement around daily activities of living and 
social activities, a therapy preferences statements and a statement of symptom 
management goals. Results: Of 25 patients, 14 responded to an outcomes survey: 
10/14 (71%) of the respondents were female, with a range of 30-72 years of age 6/14 
(42.9%) consulted 5 or more HCPs and 9/14 (64.3%) had 5 or more healthcare visits 
for their healthcare issue prior to completing the worksheet 9/14 (64.3%) indicated 
they had some miscommunication with their HCP regarding medication A major-
ity of patients had received costly blood tests (81.8%), X-rays (72.7%), and MRI/CATS 
scans (63.6%) for their healthcare issue Most patients (78.6%) used the worksheet to 
have a discussion around a new treatment option they hadn’t previously discussed, 
and almost half 6/14 (42.9%) were able to get a diagnosis for a healthcare issue not 
previously diagnosed using the worksheet; Many [9/14 (64.3%)] said the worksheet 
helped reduce office-visit related anxiety and helped them discuss symptom man-
agement [8/14 (57.2%)]. ConClusions: This simple web-based tool was useful in 
facilitating communication between patients and their HCPs, which led to diagno-
sis, receiving new treatments, and better symptom management, even in patients 
with long-standing healthcare issues, multiple visits, extensive testing, and multiple 
healthcare providers.
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objeCtives: Identify the current and future relevance of Patient Reported 
Outcomes (PROs) among U.S. payers making patient access decisions for pharma-
ceuticals Methods: Double blind, semi-structured telephone interviews with 12 
U.S. payers, including: National and regional commercial payers; Accountable Care 
Organizations; Pharmacy Benefit Managers; Self-insured employers; Actuaries; 
Veterans Affairs; and Department of Defense. Interviews included open-ended 
questioning and structured rating scales where 10= highest and 1= lowest possible 
score per concept. Results: Payers perceive PROs as the, “Consequences of the 
disease and drug as assessed by the patient...” Average rating scale responses were: 
How relevant are PROs? today? = 3.7 in 5 years? = 6.4 Would you like to see more PRO 
evidence? today? = 6.1 in 5 years? = 6.6 Should pharmaceutical companies invest 
more in PROs? today? = 5.6 in 5 years? = 6.3 The sum of the 6 scales (min= 6, max 
= 60) ranged from 12 to 58, highlighting diversity across payers. PRO relevance was 
associated with the duration of enrollment and thus total amount of risk. DoD and 
ACOs reported the highest relevance, National Commercial Health plans the lowest. 
Education was consistently identified as a need to aid interpretation of PRO data to 
support patient access decisions. ConClusions: Payers’ reliance on PRO data will 
increase in the next five years, especially in symptomatic conditions without objec-
tive measures of success. PRO evidence is valued as a unique predictor of clinical 
and economic outcomes and as a key element of performance and quality ratings. 
Respondents showed interest in pharmaceutical companies’ increasing use of PROs 
in clinical trials, creation of real world evidence and supporting PRO education.
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objeCtives: The objective of this research is to evaluate whether the 2009 FDA PRO 
Guidance leads to development of similar measures when followed by different 
researchers in the same disease. Psoriasis was selected as a case study, because 
two companies recently published patient-reported outcome measures to assess 
the severity of psoriasis-related symptoms: the Psoriasis Symptom Inventory (PSI) 
and the Psoriasis Symptom Diary (PSD). Methods: Full-length publications related 
to the development of the PSI and PSD were reviewed. The following information 
regarding the development process and key aspects pertinent to the PRO Guidance 
were extracted and compared: patient population, development steps (literature 
review, involvement of patients during item development), psychometric proper-
ties, content of final measure, recall period, response options, and scoring. The 
authors conducted a qualitative evaluation of the differences between the meas-
ures. Results: Five publications regarding the development of the measures were 
identified (PSI, n = 3; PSD, n = 2). Both measures focus on symptoms of moderate 
to severe psoriasis. Both measures were based on literature reviews, patient input, 
and expert opinion and had similar psychometric properties. Both measures have 
a 24-hour recall period. However, the measures consist of different numbers of 
disease-specific symptoms (PSI = 8; PSD = 6). The PSI consists of 8 items, all of which 
measure symptom severity. The PSD consists of 16 items (bother of symptoms = 8, 
severity of symptoms = 6, skin color = 1, hiding skin = 1). Additionally, the measures 
assess symptoms differently. The PSI uses a 5-point Likert scale, while the PSD uses 
an 11-point numeric rating scale; both measures equate higher scores with greater 
severity. ConClusions: This example demonstrates that when different experts 
develop patient-reported outcome measures to assess identical concepts and to 
align with the FDA PRO Guidance, the result is similar but not identical.
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objeCtives: There is a dearth of evidence on factors influencing prescription plan 
switching versus switching from brand name drug to generic one. However, either of 
this switching decision could significantly impact health and wellbeing of Medicare 
beneficiaries. The objective of the present study was to better understand the rela-
tive impacts of individual versus prescription plan level characteristics on both of 
these switching decisions. Methods: Medicare beneficiaries participated in the 
2007 HRS prescription drug survey and 2009 HRS well-being survey and enrolled in 
Medicare part D (stand-alone), HMO, fee-for service or Advantage plans. The study 
sample includes 1298 individuals responded both years surveys. . Random inter-
cept multinomial logistic regression model was estimated. Results: Only 5% of 
sample members switched into different prescription plans in both 2007 and 2009, 
while about 24% individuals switched from brand name drugs to generic product to 
save prescription drug costs. An outcome variable of interest includes 4 categories: 
switched into different part D plan, switch from brand to generic drug, thought about 
switching but did not actually switch and didn’t do anything. The main covariates 
of interest include individual and plan level characteristics. Compared to “didn’t do 
anything” Individuals were more likely to switch to different prescription plan (13%) or 
switched into generic drug from brand name (25%) if they were using higher number 
of prescription medications (p< 0.04). Individuals having plans with good customer 
service was 54% less likely to switch into different part-D plan. Compared to “didn’t 
do anything” individuals were 123% more likely to stay on the same plan being not 
satisfied with the current plan if they experience “inertia” in the plan choice deci-
sion. ConClusions: Unobserved plan level characteristics matter in part-D plan 
switching or drug switching decisions. Consumer inertia and plan’s customer service 
quality appear to be important factors influencing these switching decisions.
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objeCtives: As healthcare becomes more patient-centered, patient-reported out-
comes (PROs) are assuming a growing role in different aspects of care. Avalere sought 
to define a conceptual framework on the criteria for defining, implementing, and 
translating PROs into valid, reliable measures of performance. Methods: Conducted 
a structured literature review to identify influencers in the translation of PROs, issues 
that impact translation, and relationships between key variables. Results: Various 
